The global hemoglobinopathy drugs market is anticipated to grow at a significant CAGR during the forecast period (2024-2031). Hemoglobinopathy is a group of hereditary blood disorders involving an abnormality in the structure of haemoglobin. These disorders include both sickle cell disease (SCD) and thalassemia. Common symptoms of the condition include severe pain, shortness of breath, enlarged spleen, and growth problems in children. Other types of hemoglobinopathies linked to the structural haemoglobin variants are HbS, HbE, and HbC.
Get Free Sample link @ https://www.omrglobal.com/request-sample/hemoglobinopathy-drugs-market
The major factor that is expected to boost the global hemoglobinopathy drugs market includes the increasing incidence and prevalence of sickle cell disease, which will propel the growth of the global hemoglobinopathy treatment drugs market over the forecast period. For instance, according to the data published in Centers for Disease Control and Prevention in October 2019, SCD affects around 100,000 Americans every year. Moreover, as per the same source, around 1 in 13 African-American babies are born with sickle cell trait.
The global hemoglobinopathy drugs market analysis includes some of the key market players such as GlycoMimetics Inc., Pfizer Inc., Anthera Pharmaceuticals Inc., Eli Lilly and Company, and Mast Therapeutics, among others. To maintain a strong position in the market, these market players are adopting various strategic moves, such as product launches, partnerships, collaborations, and mergers and acquisitions. For instance, in July 2018, the European Medicines Agency’s Committee for Medicinal Products for Human Use granted the bluebird bio LentiGlobin therapy for use in the treatment of hemoglobinopathy disorders among patients.
Full report of Hemoglobinopathy Drugs Market available @ https://www.omrglobal.com/industry-reports/hemoglobinopathy-drugs-market
Market Coverage
- Segment Covered
- Regions Covered- Globally
Competitive Landscape: GlycoMimetics Inc., Pfizer Inc., Anthera Pharmaceuticals Inc., Eli Lilly and Company, and Mast Therapeutics, among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominates the market in base year?
- Which segment and region will project fastest growth in the market?
- How COVID-19 impacted the market?
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Hemoglobinopathy Drugs Market by Segment
By Type
- Hydroxyurea
- Glutamine
- Zynteglo
- Other
By Distribution Channel
- Retail Pharmacy
- Hospital Pharmacy
- Online Pharmacy
Reasons to Buying From us –
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/hemoglobinopathy-drugs-market
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
